{"category": "ham", "to_address": "\"Nicholas Lewin-Koh\" <nikko@hailmail.net>", "from_address": "\"Spielas Bates\" <bates@stat.wisc.edu>", "subject": "Re: [R] R vs. Splus in Pharma/Devices Industry", "body": "On 6/15/07, Nicholas Lewin-Koh  wrote:\n> Hi,\n> I just saw this thread. This issue, and the larger scale issue of open\n> source in industry\n> is being addressed. One has to realize that the behemoth that is the\n> clinical aperatus\n> of the pharma industry is very conservative and very slow to change. In\n> many cases\n> switching to R would meean changing a great many processes all based on\n> legacy code. One\n> of the big issues is that the industry demands consistency not\n> necessarily correctness.\n>\n> All that said there are a great many areas where R could be used that\n> would not impact\n> regulatory submission, data security etc. Many in pharma are quietly\n> working on this,\n> but steps are small and incremental. Development takes time in industry\n> because of the amount of\n> documentation necessary. All this impacts the \"free\" nature of R and\n> cost and risk (From the industries\n> perspective) need to be justified.\n\n> Probably when the statistical community is using Z big pharma will be\n> ready to use\n> R. %P\n\nI think you mean A, not Z.  First there was S, then there was R.\n\n______________________________________________\nR-help@stat.math.ethz.ch mailing list\nhttps://stat.ethz.ch/mailman/listinfo/r-help\nPLEASE do read the posting guide http://www.R-project.org/posting-guide.html\nand provide commented, minimal, self-contained, reproducible code.\n\n"}